Fast Facts
Our clinical trials portfolio includes:
- More than 40 research studies
- More than 10 Pediatric-focused studies
- Five phase-1 Trials
- First-In-Human treatments
- Investigational New Drugs developed at UF
Featured Trial
PNOC 020
A Phase I/II Study of RNA-lipid particle (RNA-LP) vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM).
Subject inclusion criteria:
- Age: 21 Years and older (Adult, Older Adult)
- Histopathologically proven newly-diagnosed de novo GBM (WHO Grade IV glioma) (secondary GBM not eligible) that is MGMT unmethylated.
- The tumor must have a supratentorial component.
- Bone Marrow, Renal and Hepatic tests
See full inclusion criteria and learn more about the PNOC 020 Clinical Trial
Contact Marcia Hodik to hear more about the PNOC 020 Clinical Trial.
Browse or search current neurosurgery clinical trials
ACTION
Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas
Adult or Pediatric?
Pediatric
Disease
Brain Tumor
Disease Type
Newly Diagnosed
High-Grade
Glioma
Drug
Temozolomide
Drug Type
Chemotherapy